Δράσεις Μελών COVID-19

Abbvie - Members Update

In late January, the Chinese health authorities identified Aluvia (lopinavir/ritonavir) as a potential treatment for COVID-19 and requested supply. AbbVie donated approximately $2 million (USD) of Aluvia as an experimental option to help address the growing health crisis. AbbVie is also working with the WHO to ensure a coordinated global effort.

Astra - Members Update

Through its scientific expertise in infectious disease and proprietary antibody discovery technology, AstraZeneca has rapidly mobilized its research efforts to discovering novel coronavirus-neutralising antibodies as a treatment to prevent COVID-19 disease.

AstraZeneca is also donating nine million face masks to support health care workers around the world as they respond to the COVID-19 global pandemic. The company has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organization, to identify countries in greatest need.

In addition to these donations, AstraZeneca is accelerating the development of its diagnostic testing capabilities to scale-up screening and is also working in partnership with governments on existing screening programs to supplement testing. Most recently, AstraZeneca has partnered with the University of Cambridge and GSK in the UK to support the Government’s response to the pandemic in expanding its testing capacity.

To help ensure the continued supply of its medicines to patients, AstraZeneca will screen employees across its manufacturing and supply network. The company’s research and development teams have also been working expeditiously to identify monoclonal antibodies to progress towards clinical trial evaluation as a treatment to prevent COVID-19. More than 50 virology, immunology, respiratory and protein engineering experts across research, clinical, regulatory and manufacturing are placing the highest priority on developing a treatment to minimize the global impact of the disease.

Additionally, AstraZeneca will initiate a randomized, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients. The trial design is based upon strong scientific evidence supporting the role of the Bruton’s tyrosine kinase (BTK) pathway in the production of inflammatory cytokines and on encouraging early clinical data. Calquence is a next-generation, highly selective BTK inhibitor currently used to treat certain types of blood cancers.

Bayer - Members Update

Bayer AG has joined forces with other manufacturers in the COVID-19 Therapeutics Accelerator Initiative, initiated by the Bill & Melinda Gates Foundation, thereby opening up their vast compound library to find and develop effective novel compounds against COVID-19. Bayer also responded to the European Innovation Medicine Initiative’s call for the “Development of therapeutics and diagnostics combatting coronavirus infections” with an in-kind contribution covering the screening of a molecular target against the Bayer substance library. They are ready to cooperate with international organizations, governments, authorities and scientific institutions around the globe to jointly explore options to better understand how Chloroquine (a product discovered by Bayer) can contribute to the treatment of patients infected with COVID-19. Bayer is also providing assistance to affected regions and countries. For instance, the company is supporting hospitals in Lombardy, Italy, with a donation of one million euros to help procure urgently needed equipment for intensive care units. Besides Italy, Bayer has already sent considerable financial and material support to China to help contain the pandemic.

Boehringer Ingelheim - Members Update

Boehringer Ingelheim immediately identified the areas of expertise, where we can best contribute to developing therapies for COVID-19 in close collaboration with academic researchers, international institutions and others in the pharma industry. Boehringer Ingelheim has joined a fast track call for project submissions to develop therapies and diagnostic tools initiated by the Innovative Medicines Initiative (IMI) of the European Union to accelerate the development of potential therapies for COVID-19. Boehringer Ingelheim is working to develop neutralizing antibodies against the SARS-CoV-2 spike protein. In addition, we are investigating our existing pipeline and in-market compounds as well as compounds from former HIV and HCV research activities. Furthermore, Boehringer Ingelheim is conducting a computational screening of its entire molecule library of more than one million compounds with the aim of identifying novel small molecules with activity against the virus.  Learn more about Boehringer Ingelheim’s engagement in the fight against COVID-19.

BMS - Members Update

Bristol Myers Squibb (BMS) has donated approximately $750,000 in cash and needed products to Wuhan city and Hubei province, through the Shanghai Red Cross Society. The BMS Foundation has separately provided support to two relief partner organisations to provide more than one million items of personal protection, including masks, gloves and coveralls, to healthcare professionals in key hospitals in Wuhan City. The BMS Foundation is also working closely with partners to ensure medical supplies are quickly distributed to frontline medical professionals treating patients in Wuhan. BMS is also diligently monitoring manufacturing and supply facilities across the globe, including in areas which have seen a greater impact, and at this time they do not anticipate disruptions to the supply of medicines for patients due to COVID-19.

Chiesi - Members Update

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic. To date, Chiesi Group support and donations included: donation of 50.000 units of sanitizing hand gel to public transport operators and personal protective equipment to hospitals; Collaboration with associations of general practitioners on advice and guidance, providing support for the purchase of respiratory equipment in hospitals that support COVID-19 patients; Partnership with local volunteer associations to offer financial or material donations and a commitment to maintain support as we identify new areas of intervention that the company can address.

Chiesi has announced today a new €3 million fund to support efforts to address this crisis in Italy. This fund will support a range of actions including donations of personal protective equipment, ventilators and sanitising gel in response to requests from hospitals and other health institutions. The company has also made direct donations of drugs for respiratory diseases to hospitals in China and Italy. Chiesi has also set up a process where team members in Italy can donate “virtual” hours of work to an association of volunteers in Parma to support emergency response. The company converted the donated hours worked into a monetary donation, which was then doubled by the Chiesi Group. In two weeks close to € 70.000 have already been collected.

GlaxoSmithKline - Members Update

Supporting research and production of candidate COVID-19 vaccines
GlaxoSmithKline (GSK) is collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine doses to be produced, and therefore contributing to the protection of more people.

GSK has announced that it has joined forces with Sanofi, bringing together two of the world’s largest vaccines companies in an unprecedented collaboration to fight COVID-19. The two companies will combine innovative technologies to develop an adjuvanted COVID-19 vaccine, which is expected to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021. This would be a significantly faster timeline than for normal vaccine development and teams from both companies are starting work on this urgently.

In addition to Sanofi, GSK is also collaborating with the University of Queensland, Clover Biopharmaceuticals and Xiamen Innovax Biotech Co., Ltd. in the hope that there will be a number of successful vaccines developed with its pandemic adjuvant technology.

Overall GSK does not expect to profit from its portfolio of collaborations for COVID-19 vaccines during this pandemic. As any short-term profit generated will be invested in support of coronavirus related research and long-term pandemic preparedness, either through GSK’s internal investments, or with external partners.  Making its adjuvant available to the world’s poorest countries will also be a key part of the company’s efforts, including donations of this adjuvant, by working with governments and the global institutions that prioritise access.

Screening and research into new medicines
In addition to Vaccines GSK is also supporting screening and research into potential medicines for COVID-19.

GSK has announced a collaboration with Vir Biotechnology to use Vir’s monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options for COVID-19.

GSK is entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from its libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.

GSK is also evaluating its marketed medicines and those in development, to determine if any could be used beyond their current indications, and evaluating options to make available our specialised laboratory space to help in research and testing of COVID-19.

Helping frontline health workers and offering expertise
GSK is donating $10 million to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to support WHO and partners prevent, detect and manage the pandemic, particularly where the needs are the greatest.

GSK is also donating surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees, to enable those with medical or specialist expertise to provide support to frontline health workers and national governments.

Taking action to deliver high-demand consumer healthcare products
GSK Consumer Healthcare is prioritising actions in its supply chain to deliver more consumer products that are in high demand, due to COVID-19. This includes increasing production for pain relief brands and multi-vitamins and dietary supplements.

Ipsen - Members Update

  • Ipsen Global donated €2 million to the Institut Pasteur to support the 21 research projects currently ongoing to combat COVID-19.
  • Ipsen Benelux donated 700 medical masks to various hospitals in Gent for healthcare workers on the front lines.
  • Ipsen France is supporting France Biotech, MedTech and France Digital in a public-private initiative, “Health Innovation Coalition – Health Crisis” to alleviate congestion in the healthcare system and ensure patients with diseases unrelated to COVID-19 experience no disruption in treatment. Regional initiatives in France also include donations of 500 gowns to local hospitals, while ensuring patients are still able to receive the medicines they need, donation of medical masks and medical gloves to local healthcare workers.
  • Ipsen Greece donated two ventilators for intensive care units following a call from local health authorities who were anticipating a shortage in medical equipment.
  • Ipsen Iberia is working on a program where all coupon restaurants of the teams for March and April will be donated to the Red Cross.
  • Ipsen Italy allocated its entire 2020 Grants and Donations budget to the Bergamo Hospital in northern Italy, one of the regions hit hardest by COVID-19, for the purchase of ventilators and non-invasive ventilating materials. Furthermore, a sum of money will be donated to the Italian Civil Protection, which coordinates health efforts throughout the country, plus a newly created delivery service of oral oncological drugs for patients with kidney cancer.

Information on other ongoing initiatives outside Europe can be found here.

J&J and Janssen - Members Update

On 30 March 2020 Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorisation in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

Thanks to J&J diversification, size and scale, it has been able to take rapid action across its Pharmaceutical, Consumer and Medical Devices businesses, as well as their Supply Chain and other supporting functions, to help stay ahead of the pandemic. Beyond seeking an optimal vaccine candidate, to date J&J efforts have included: Making available currently marketed antivirals to test their potential efficacy; Collaborating with industry partners to screen a library of antiviral molecules, with the aim to identify potential treatments; Working with regulators, healthcare organisations, institutions and communities worldwide to maximise their research platforms; Supporting healthcare professionals through making available tools, such as personal equipment (for instance via a RMB 1 million donation to the China Red Cross Foundation), a surgical generator and other devices for the newly-built isolation hospitals, protective suits, and a million masks among others; Last but not least, working with Governments to bring support on the ground, such as the ongoing cooperation with Belgium to use Janssen own laboratories in Beerse to significantly increase the capacity for COVID-19 testing. Cooperation also includes the new production of disinfectant hand liquid in Janssen Manufacturing Plant in Geel (Belgium).

Menarini - Members Update

The Menarini Group has repurposed one of its manufacturing plants in Italy (normally dedicated to topical gels) to the manufacture of hand sanitising gel. The production capacity has also been upscaled passing from an initial 5 tonnes to 15 tonnes per week and is set to increase even further. The sanitising gel has been donated free of charge to hospitals and front-line personnel engaged in the battle against COVID-19, along with a number of lung ventilators and thousands of medical coveralls, gloves, face shields, goggles and, very shortly, 700.000 face masks.

The Menarini Group is also providing financial support as well as in-kind donations to organisations in the front line across Europe and beyond, commented Dr Eric Cornut, Chairman of Menarini Group.

Merck - Members Update

As part of the global effort to investigate potential therapeutics for COVID-19 and their support of independent research, Merck recently donated a supply of interferon beta-1a (Rebif®) to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. To date, Merck’s interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.  Merck has also supported China’s fight against the coronavirus with multiple donation efforts in cash and kind to three well respected local charitable organizations in order to support much needed medical aid. This includes products to support local institutions and invitro diagnostic manufactures to accelerate research, as well as virus diagnosis and testing efforts and personal protective equipment.  Overall, the spread of the coronavirus also stresses the importance of pandemic preparedness – a topic that we continue to support with our € 1 million Merck Future Insight Prize.

Novartis - Members Update

Novartis announced a broad range of initiatives to respond to COVID-19 pandemic. The Novartis COVID-19 Response Fund will provide USD 20 million in grants to support public health initiatives designed to help communities manage challenges posed by the pandemic. The company has established an accelerated global review process for individual grants of up to USD 1 million. Novartis has also entered new collaborative research efforts such as the COVID-19 Therapeutics Accelerator, as well as a COVID-19 directed partnership organised by the Innovative Medicines Initiative (IMI).  Additionally, in response to an urgent call for research and development on coronavirus, issued by EFPIA, Novartis is contributing by making available several compounds from its libraries that are considered suitable for in vitro antiviral testing. In addition, the company is continuously evaluating other existing products to see if any could be utilized beyond their approved indications in response to the pandemic. A first identified product is hydroxychloroquine, currently under evaluation in clinical trials for the treatment of COVID-19, and of which Novartis committed to donate up to 130 million doses. Novartis Sandoz division will pursue appropriate regulatory authorisations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it. Earlier this month, Sandoz, the company’s generics and biosimilars division, was the first company to commit to keeping prices stable for a basket of essential medicines that may help in the treatment of coronavirus cases. The company has also activated mitigation plans to ensure ongoing drug supply and smooth operations for its over 500 clinical studies.

Η δέσμευση της Novartis Hellas στους ασθενείς κατά τη διάρκεια της πανδημίας του COVID-19

Η δέσμευση της Novartis Hellas στους  ασθενείς κατά τη διάρκεια της πανδημίας του COVID-19

  • Εγκαινιάζει πρόγραμμα «Δωρεάν παράδοσης κατ’ οίκον» για φαρμακευτική αγωγή ασθενών με σοβαρά χρόνια νοσήματα
  • Υποστηρίζει ασθενοκεντρικές πρωτοβουλίες που ενθαρρύνουν τη χρήση ψηφιακών εργαλείων
  • Σχεδιάζει για 2η συνεχή χρονιά την υλοποίηση του European Patient Innovation Summit και του Σεμιναρίου Ανάπτυξης Ικανοτήτων & Ενδυνάμωσης που απευθύνονται σε συλλόγους ασθενών, προσαρμοσμένα στην ψηφιακή εποχή

Press Release

Infographic footprint

Η Novartis Hellas ανακοινώνει σειρά πρωτοβουλιών για την αντιμετώπιση της πανδημίας COVID-19

Η Novartis Hellas προχωρά σε δωρεές σε είδος και πρωτοβουλίες που, μεταξύ άλλων, περιλαμβάνουν:

  • Προσφορά ιατρο-τεχνολογικού εξοπλισμού σε ΜΕΘ
  • Ενίσχυση του τεχνολογικού εξοπλισμού του Πανεπιστημιακού Νοσοκομείου Ιωαννίνων
  • Επέκταση της τηλε-εργασίας για τους εργαζόμενους του Ινστιτούτου Παστέρ
  • Yποστήριξη εργαζομένων και των οικογενειών τους

Press Release

Novo Nordisk - Members Update

Novo Nordisk is helping the health authorities fight COVID-19 with a variety of initiatives. In response to a shortage of hand sanitiser products in Denmark, we are donating 20 tonnes of ethanol from our production facility in Kalundborg to help bridge the gap. In collaboration with partners including Carlsberg, the ethanol will be manufactured into hand sanitizer and provided to the Danish healthcare system in the coming days. As part of ongoing efforts to provide timely support and resources to the fight against COVID-19, Novo Nordisk will also donate 2,000 protective masks. These will be sent immediately to authorities in Southern Denmark where the need is most pressing. We have made financial donations to the Red Cross in China, as well as to hospitals in Croatia, Greece and Italy to help their efforts to treat and prevent the spread of COVID-19. Testing is a critical aspect of global efforts to slow the spread of COVID-19 and as of today, we are dedicating one of our HQ R&D laboratories outside Copenhagen towards this key task. In the UK, our Research Centre in Oxford is lending out laboratory equipment to the NHS to support COVID-19 testing. In Italy, we have given an unconditional contribution to Senior Italy FederAnziani, the largest federation for senior citizens, to establish a national toll-free number to provide psychological support and a listening to senior citizens isolated in their homes. The contribution also goes to support the public awareness campaign: Seniors & Coronavirus: rules against contagion from fake news and scams. For a full snapshot of our efforts click here.

Pfizer - Members Update

As a global healthcare company, we remain committed to supporting the relief efforts in impacted areas, to help governments and health partners fight against the disease. ​​

Our Science
For 170 years, our scientists and experts at Pfizer have addressed global health challenges. As part of our immediate response, we identified anti-viral compounds in our libraries which may have potential to address COVID-19. We are engaging with a third party to screen these compounds under an accelerated timeline and currently expect to have the results back by the end of March. We are also working with our partner BioNTech to co-develop a potential COVID-19 vaccine.

On a broader scale, Pfizer is committed to working as one team across the industry to harness our scientific expertise, technical skills and manufacturing capabilities to combat this evolving crisis. We have made five promises that will help scientists more rapidly bring forward therapies and vaccines to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises.

Our Relief Efforts
Pfizer is grateful to the medical professionals on the front lines of this pandemic. We have an extensive global network of medical practitioners and experts, many of whom feel called to support their communities in the diagnosis, treatment and provision of public health support during this time. We respect their courage and selflessness to serve and have established a medical service policy that will allow these colleagues up to 13 weeks of paid leave, or longer if necessary, to provide this support.

Pfizer and the Pfizer Foundation have a long history of addressing humanitarian disasters. We are working with governments and international NGOs to respond to the COVID-19 pandemic by donating much needed medications and vaccines and working to support front line health workers.

In Italy, Pfizer’s affiliate is making available, free of charge, €2.5 million worth of medicines and vaccines that can be used in prevention and management of serious consequences related to COVID-19 in impacted regions. Pfizer is also dedicating resources to ensure safe and timely home delivery of essential drugs for patients with life threatening and rare diseases, such as haemophilia.

Lilly - Members Update

Lilly joined forces with AbCellera Biologics to co-develop antibody products for the treatment and prevention of SARS-CoV-2, the virus that causes COVID-19. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.

Pierre Fabre - Members Update

In the context of the unprecedented public health emergency caused by Covid-19, hand sanitiser has become a staple product in the fight to protect public health. As the long-standing partner of dispensing pharmacists, the Pierre Fabre Group could not simply look on without taking action as the risk of shortages began to threaten a product that has now become a vital part of daily life. Since mid-March, staff from the Pierre Fabre dermo-cosmetics production and packaging plant in Soual, southwest France, have been fully mobilised to produce hydroalcoholic gel.

Roche and Genentech

Roche is doing everything it can to contribute to fighting the pandemic. Their people are working day and night with the aim of developing, manufacturing and supplying key tests and medicines where they are needed most. They are partnering with healthcare providers, laboratories, authorities and organisations to support local response, and they are committed to help make sure that patients receive the tests, treatment and care they need.

Roche’s contribution focuses on our existing strengths and capabilities:

COVID-19 testing: They are committed to providing testing solutions for the world’s most challenging healthcare emergencies.  In mid-March they launched a high-volume molecular test intended for the qualitative detection of the SARS-Cov-2 virus that causes the COVID-19 disease. On April 19, they announced  development and upcoming launch of Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the virus.

Investigating treatment options: While there are currently no approved medicines for the treatment of COVID-19, Roche is actively involved in understanding the potential of its existing portfolio and is researching options for the future.  On 19 March, they  announced initiation of COVACTA –  a global Phase III randomised, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of intravenous tocilizumab plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. They have also initiated an internal early research programme focused on the development of medicines for COVID-19.

People: Roche knows its people are both highly skilled and passionate about their purpose. They are proud of the work they are doing to support their local communities, from helping out in local healthcare facilities to answering requests from call centres.

In these exceptional times, Roche stands together with governments, healthcare providers and all those working to overcome the pandemic

Sanofi - Members Update

In view of the rapidly changing and ever-challenging COVID-19 pandemic situation, Sanofi is leveraging its expertise and experience in a number of ways to address this public health crisis.

In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), Sanofi is taking previous work on a SARS vaccine candidate to advance a novel vaccine for COVID-19 using its recombinant DNA technology. The company is also collaborating with Translate Bio to develop a novel mRNA vaccine.

Sanofi is investigating whether its existing medicines may be effective in treating COVID-19. The first non-U.S. patient has been treated as part of a global clinical program evaluating whether Sanofi and Regeneron’s rheumatoid arthritis drug may ameliorate the life-threatening complications of COVID-19 infections. Sanofi is also working with local governments and health authorities that have officially requested the anti-malarial drug for use in COVID-19.

Apart from coordinating with the Coalition for Epidemic Preparedness Innovations (CEPI) to share its vaccine R&D experience, Sanofi is in weekly contact with the European Commission and EMA to help monitor the impact of COVID-19 on medicines and vaccines supply in Europe.

Sanofi’s recently announced its intention to  create a leading active pharmaceutical ingredients (API) company based in France by combining six of its European sites. While it is unrelated to COVID-19, it is relevant to the current situation. API are the essential molecules responsible for the beneficial effects used in the composition of any drug. Sanofi’s aim is to secure significant API manufacturing and supply capacities that are critical for patients in Europe, and beyond. Strong political support for this type of initiative is needed.

Sanofi and GSK have also signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies: Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology; and GSK will contribute its proven pandemic adjuvant technology.

Servier - Members Update

Since the beginning of the crisis, Servier is committed to helping those who fight against the Covid-19 pandemic. Beyond supporting the research efforts to prevent and treat the coronavirus disease, our company has, to date, contributed to solidar​y initiatives in more than 35 countries. Servier is assisting health authorities and hospitals by providing hand sanitizer gel and urgently needed personal protection equipment (more than 300 000 masks, gloves and other protective gear donated directly by Servier or through industry association initiatives). Servier is also joining forces with foundations, NGOs and associations (such as the Chinese Red Cross and Americares in India) by making donations to help caregivers and populations affected by the virus. In France, many healthcare professionals employed by Servier have volunteered to join medical staff on the front line against the virus. Servier also brings its expertise and financial support to the multi-stakeholders partnership “Health Innovation Coalition – Health Crisis″ that aims to develop innovative solutions to relieve congestion in the healthcare system and ensure patients with chronic diseases continue to be treated.

As a global leader in healthcare, Servier puts its best efforts to ensure the continuity of its operations and provide full access to its medicines for patients who rely on them. 98% of Servier’s innovative medicines’ active ingredients are produced in Europe.

Takeda - Members Update

Takeda is committed to taking steps in the fight against the rapidly spreading novel coronavirus by initiating development of a plasma-derived therapy, designated TAK-888, with the potential to treat hospitalized COVID-19 patients and to prevent infection in frontline healthcare workers. TAK-888, a polyclonal hyperimmune globulin (H-IG) is an investigational treatment prepared from the plasma of individuals who have fully recovered from COVID-19, and whose blood contains antibodies that can fight the virus. Once donated, the “convalescent” plasma would then be transported to manufacturing facilities where it undergoes effective virus inactivation and removal processes, and then purified into the H-IG.  Takeda is collaborating closely with regulatory agencies, governments and healthcare partners to advance this program. If successful, it is anticipated that this potential therapy could be available within nine to 18 months.

UCB - Members Update

These are challenging times. The surge of cases of COVID-19 is having a profound impact on people around the world, putting pressure on our health systems and disrupting all our daily lives.

It is heartening to seeing the wave of solidarity coming from companies, organizations and individuals. At UCB we are also looking to do our part.

Our action is based on three pillars:

·       Contributing to basic research and treatment development

·       Offering our expertise to increase local testing capabilities

·       Supporting locally and globally through donations as well as direct assistance to patients and partners.

Read more here